Department of Cardiology, Faculty Division Rikshospitalet, University of Oslo, Oslo, Norway.
Eur J Cancer. 2010 Dec;46(18):3425-33. doi: 10.1016/j.ejca.2010.08.004. Epub 2010 Sep 9.
C-reactive protein (CRP) is a marker of cardiovascular disease (CVD). There is conflicting evidence regarding CRP as a marker of future cancer. We studied whether CRP predicts CVD and consecutive cancer in testicular cancer survivors (TCSs).
During 1998-2001, 586 TCSs with a high sensitivity CRP ≤ 10 mg/L were identified median 11 (4-21) years after treatment (FU-1). A second follow-up survey (FU-2) was conducted median 8 (6-9) years after FU-1. At FU-2 we obtained information about post-FU-1 CVD (cardiovascular death, nonfatal myocardial infarction, stroke, revascularisation or heart failure). Information about post-FU-1 non-germ cell cancer and cardiovascular death in all patients were retrieved from the Cancer Registry of Norway.
After FU-1 31 (5.3%) of 586 patients developed non-germ cell cancer (excluding localised prostate cancer), while 28 (4.9%) developed CVD. Cox regression analyses showed that patients with CRP ≥1.5mg/L had 2.21 (95% CI 1.04-4.70) times higher risk of developing non-germ cell cancer and 2.79 (95% CI 1.22-6.34) times higher risk for CVD compared to patients with CRP <1.5mg/L at FU-1.
In long-term TCSs, CRP may serve as a potential marker of cardiovascular events and a second cancer.
C-反应蛋白（CRP）是心血管疾病（CVD）的标志物。关于 CRP 是否是未来癌症的标志物，目前存在相互矛盾的证据。我们研究了 CRP 是否可预测睾丸癌幸存者（TCSs）的 CVD 和后续癌症。
1998 年至 2001 年期间，在治疗后 11 年（FU-1）中位数（4-21 年），确定了 586 名 CRP≤10mg/L 的高敏 CRP 的 TCSs。在 FU-1 后进行了第二次随访调查（FU-2）。在 FU-2 时，我们获得了 FU-1 后 CVD（心血管死亡、非致命性心肌梗死、中风、血运重建或心力衰竭）的信息。所有患者的 FU-1 后非生殖细胞瘤癌症和心血管死亡信息均从挪威癌症登记处检索到。
在 FU-1 后，586 名患者中有 31 名（5.3%）发生了非生殖细胞瘤癌症（不包括局部前列腺癌），而 28 名（4.9%）发生了 CVD。Cox 回归分析显示，CRP≥1.5mg/L 的患者发生非生殖细胞瘤癌症的风险比 CRP<1.5mg/L 的患者高 2.21 倍（95%CI 1.04-4.70），发生 CVD 的风险高 2.79 倍（95%CI 1.22-6.34）。
在长期的 TCSs 中，CRP 可能是心血管事件和第二癌症的潜在标志物。
